Summary of Entrada Therapeutics FY Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 03, 2026 Key Points Industry and Market Context - **Duchenne Muscular Dystrophy (DMD) Market**: Estimated at $5 billion in the U.S. with limited competitive penetration and significant unmet clinical needs [4][14] - **Myotonic Dystrophy Type 1 (DM1)**: Partnership with Vertex, with potential access to up to $485 million in milestones [6][19] - **Inherited Retinal Diseases (IRDs)**: Addressing a high unmet clinical need with no approved therapeutics for conditions like Usher syndrome type 2A [20][21] Clinical Pipeline and Milestones - **DMD Programs**: - Four potential clinical readouts expected in 2026 from exon 44 and exon 45 studies [2][3] - First cohort data for ENTR-601-44 expected in Q2 2026, with a second cohort by year-end [7][23] - Aiming for double-digit dystrophin production in the first cohort [30][31] - **DM1 Program**: Vertex's VX-670 is in a Phase I/II study, with dosing completion expected in mid-2026 [20][19] - **Ocular Disease Programs**: ENTR-801 targeting Usher syndrome type 2A, with IND-enabling studies planned [21][22] Financial Position - **Cash Runway**: Approximately $296 million available until Q3 2027 [5][24] - **Funding Strategy**: Focus on non-dilutive capital through partnerships, exemplified by the Vertex collaboration [51] Strategic Focus - **Differentiation and De-risking**: Emphasis on creating best-in-class therapeutics through innovative delivery mechanisms like endosomal escape vehicles (EEVs) [11][50] - **Regulatory Strategy**: Plans for Accelerated Approval in the U.S. based on clinical data from ex-U.S. studies [14][35] Competitive Landscape - **Comparison with Competitors**: Aiming to surpass competitors like Avidity and Sarepta in dystrophin production levels [13][44] - **Market Opportunity**: Targeting approximately 30,000 patients in the U.S. and Europe with DMD, with a focus on capturing a significant market share [14][15] Research and Development - **Clinical Study Design**: Studies designed to establish safety and functional benefits, with a focus on long-term patient outcomes [41][42] - **Combination Therapies**: Potential for future combination therapies with gene therapy, depending on market dynamics and payer considerations [38] Future Outlook - **2026 as a Transformational Year**: Anticipated significant clinical data and potential regulatory milestones across DMD, DM1, and IRDs [2][24] - **Pipeline Expansion**: Continued development of next-generation oligonucleotides and EEVs for various diseases [24][50] Additional Insights - **Collaboration with Vertex**: Clear delineation of responsibilities and effective communication have been key to the success of the partnership [48] - **Focus on Patient Outcomes**: Commitment to developing therapeutics that improve the quality of life for patients, with a strong emphasis on safety and efficacy [42][39]

Dividends and Earnings Retention - The company does not intend to pay dividends on its common stock, anticipating that future earnings will be retained for business development and expansion [593]. Regulatory Compliance and Costs - The company has incurred and will continue to incur increased costs due to operating as a public company, with significant legal and compliance expenses expected to rise after ceasing to be an "emerging growth company" [601][602]. - The company is required to comply with Section 404 of the Sarbanes-Oxley Act, which mandates a formal assessment of internal control effectiveness over financial reporting, potentially increasing operational costs [602]. - The company can take advantage of exemptions from providing an auditor's attestation report on internal controls over financial reporting under the Sarbanes-Oxley Act [700]. - The company may also be exempt from complying with mandatory audit firm rotation requirements set by the PCAOB [700]. - Reduced disclosure about executive compensation arrangements is permitted for the company [700]. - The company is not required to hold nonbinding advisory votes on executive compensation or seek stockholder approval for golden parachute payments [700]. Risks and Challenges - The company faces risks related to potential material weaknesses in internal controls, which could lead to inaccurate financial reporting and decreased investor confidence [603][605]. - The company may be subject to securities litigation, which could divert management attention and incur substantial costs [608]. - Disruptions at regulatory agencies like the FDA and SEC could hinder product development and approval processes, negatively impacting the company's operations [610][611]. - The U.S. government has experienced multiple shutdowns, which could significantly impact the FDA and SEC's ability to review and process future regulatory submissions, potentially affecting the company's operations [612]. Reporting and Disclosure Exemptions - The company may qualify as a "smaller reporting company," allowing it to take advantage of exemptions from certain disclosure requirements, which could affect stock attractiveness and trading volatility [591][592]. - The company is classified as a smaller reporting company and is not required to provide extensive market risk disclosures [699]. - The company may present only two years of audited financial statements and related Management's Discussion and Analysis, limiting the historical financial data available [700]. Corporate Governance - The company has anti-takeover provisions in its bylaws that may discourage changes in control, potentially affecting stock price and investor interest [594][596].

Financial Performance - Cash, cash equivalents, and marketable securities were $295.7 million as of December 31, 2025, down from $420.0 million as of December 31, 2024, primarily due to cash used for operations[7] - Collaboration revenue for Q4 2025 was $1.3 million, and $25.4 million for the full year, compared to $37.4 million and $210.8 million for the same periods in 2024[9] - Net loss for Q4 2025 was $(39.2) million, and $(143.8) million for the full year, compared to a net income of $1.1 million and $65.6 million for the same periods in 2024[12] - Total assets decreased to $377.4 million in 2025 from $526.3 million in 2024, reflecting a reduction of about 28.2%[20] - Total liabilities decreased to $71.2 million in 2025 from $97.6 million in 2024, showing a decrease of approximately 27.0%[20] - Total stockholders' equity decreased to $306.1 million in 2025 from $428.7 million in 2024, indicating a decline of around 28.5%[20] Research and Development - Research and Development (R&D) expenses were $34.0 million for Q4 2025 and $142.3 million for the full year, an increase from $33.4 million and $125.3 million in 2024[10] - The company is on track to report data from Cohort 1 of the ELEVATE-44-201 study (6 mg/kg) in Q2 2026 and from Cohort 2 (12 mg/kg) by year-end 2026[1] - The independent Data Monitoring Committee recommended the initiation of Cohort 2 at an increased dose of 12 mg/kg in the ELEVATE-44-201 study[2] - The company plans to nominate a second clinical candidate in inherited retinal diseases later in 2026, expanding its development portfolio of genetic medicines[2] - The company expects to submit regulatory applications for ENTR-601-50 in the EU by year-end 2026[8] Cash Position - The company anticipates a cash runway into Q3 2027, supported by its current cash position[2] - Cash, cash equivalents, and marketable securities decreased to $295.7 million in 2025 from $420.0 million in 2024, representing a decline of approximately 29.7%[20]

Core Insights - Entrada Therapeutics is advancing its clinical programs, with key data expected from ELEVATE-44-201 and ELEVATE-45-201 studies in 2026, including a positive recommendation for an increased dose in the ELEVATE-44-201 study [1][2][3] Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities of $295.7 million, down from $420.0 million in 2024, with a cash runway expected into Q3 2027 [7][20] - Collaboration revenue for Q4 2025 was $1.3 million, and for the full year, it was $25.4 million, a decrease from $37.4 million and $210.8 million in 2024, respectively [8] - Research and Development (R&D) expenses increased to $34.0 million for Q4 2025 and $142.3 million for the full year, compared to $33.4 million and $125.3 million in 2024 [9] - General and Administrative (G&A) expenses were $9.6 million for Q4 2025 and $41.1 million for the full year, compared to $9.9 million and $38.5 million in 2024 [10] - The net loss for Q4 2025 was $(39.2) million, and for the full year, it was $(143.8) million, compared to a net income of $1.1 million and $65.6 million in 2024 [11] Clinical Development Pipeline - Entrada is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S., with four clinical-stage programs expected in 2026 [3] - The ELEVATE-44-201 study has completed dosing of Cohort 1, with data from this cohort expected in Q2 2026 and from Cohort 2 by year-end 2026 [3][4] - The ELEVATE-45-201 study has initiated patient dosing, with data from Cohort 1 expected in mid-2026 [3] - The company plans to submit regulatory applications for ENTR-601-50 in the EU by year-end 2026 [4] Preclinical Pipeline Expansion - Entrada has generated preclinical data for programs targeting ocular and metabolic diseases, including ENTR-801 for Usher syndrome type 2A, with a second clinical candidate expected to be announced later in 2026 [5]

Core Viewpoint - Entrada Therapeutics, Inc. (TRDA) is anticipated to report a significant year-over-year decline in earnings and revenues for the quarter ended December 2025, which could impact its stock price depending on the actual results compared to estimates [1][3]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $1.32 per share, reflecting a drastic year-over-year change of -4500% [3]. - Expected revenues are projected at $1.29 million, down 96.6% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.52%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Entrada Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -59.09%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but it is more reliable for positive readings [9][10]. - The current Zacks Rank for Entrada Therapeutics is 3, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Entrada Therapeutics was expected to post a loss of $1.04 per share but actually reported a loss of -$1.06, resulting in a surprise of -1.92% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - Overall, Entrada Therapeutics does not appear to be a strong candidate for an earnings beat, and investors should consider other factors before making investment decisions [17].

Core Insights - Entrada Therapeutics has progressed patients in Cohort 1 to the open label, Phase 2 portion of the ELEVATE-44-201 study, with data from Cohort 1 expected in Q2 2026 and Cohort 2 data by the end of the year [1][2] Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [3] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the delivery of therapeutics, aiming to improve treatment outcomes for various diseases, including neuromuscular disorders [3] Clinical Study Details - ELEVATE-44-201 is a Phase 1/2 clinical study evaluating the safety and effectiveness of ENTR-601-44 for treating Duchenne muscular dystrophy (DMD) in patients with specific gene mutations [1][2] - The study has completed dosing for Cohort 1 at 6 mg/kg and is set to escalate to 12 mg/kg for Cohort 2, with plans for a third cohort at doses up to 18 mg/kg [1][2] - The FDA granted Rare Pediatric Disease Designation to ENTR-601-44 in December 2025, which may facilitate accelerated approval processes [2]

Summary of Entrada Therapeutics Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Focus**: Development of intracellular therapeutics, particularly for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) [4][6] - **Location**: Boston, with approximately 150-160 employees [4] - **New Initiatives**: Recently entered the ocular disease space, focusing on inherited retinal diseases, starting with Usher syndrome type 1A [4] Key Data Inflection Points - **Clinical Data Releases**: - Q2 2026: First clinical data set for ENTR-601-44 program at a 6 mg/kg dose, expected to show double-digit dystrophin levels and reestablish safety [6][10] - End of 2026: Data for 12 mg/kg dose from exon 44 and additional data from exon 45 [5][7] - Vertex's DM1 program data expected mid-2026 [7] Safety and Efficacy - **Safety Database**: Established a robust safety database from non-clinical studies and healthy volunteer data [6][9] - **Dystrophin Levels**: Aiming for double-digit dystrophin levels, with confidence based on extensive non-clinical data [9][10] - **Comparison with Peers**: Expecting to outperform Avidity's del-zota data, which established roughly 25% dystrophin levels above background [10] Competitive Landscape - **Differentiation**: Entrada's cyclic cell-penetrating peptide delivery mechanism is distinct from competitors like PepGen and Sarepta, which have faced safety liabilities [11][12] - **Regulatory Flexibility**: FDA has allowed dose escalation up to 18 mg/kg, indicating a favorable therapeutic index compared to competitors [13] Functional Data and Patient Outcomes - **Functional Benefit Measurement**: While initial data will focus on safety and dystrophin production, functional benefits are expected to be assessed in later cohorts [15][18] - **Background Dystrophin Levels**: Patients in the exon 44 cohort have 6%-9% background dystrophin, which may delay observable functional benefits [16][18] U.S. Study Enrollment - **FDA Approval**: Currently approved to enroll an adult study in the U.S. with plans to start in the second half of 2026, contingent on Q2 data [24][25] - **Dose Considerations**: Current U.S. study doses capped at 1.28 mg/kg, with potential discussions for higher doses based on new data [25][27] Future Exon Programs - **Pipeline Expansion**: The same endosomal escape vehicle (EEV) technology will be used for future exons (45, 50, 51), which is expected to de-risk these programs [30][31] - **Market Potential**: Aiming to capture a significant portion of the estimated $5 billion U.S. market for DMD treatments [35] Conclusion - **Strategic Positioning**: Entrada Therapeutics is positioned to leverage its unique delivery mechanism and extensive non-clinical data to establish itself in the DMD and DM1 markets, with a focus on safety, efficacy, and patient outcomes [41][42]

Company Overview - Entrada Therapeutics focuses on treating devastating diseases with intracellular targets [2] - The company is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S. [2] - By 2026, Entrada expects to have four clinical stage programs in its DMD franchise [2] Clinical Progress - Entrada highlighted significant progress across its EEV portfolio for neuromuscular and ocular diseases [2] - The company is also making progress in its partnership for myotonic dystrophy type 1 with Vertex, specifically with the program VX-670 [2] - The year is anticipated to have several value-driving catalysts for the company [2]

Summary of Entrada Therapeutics FY Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Focus**: Treating debilitating diseases with intracellular targets, particularly in neuromuscular and ocular diseases - **Key Programs**: Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) in partnership with Vertex Key Points and Arguments Clinical Programs and Pipeline - Entrada is advancing multiple clinical programs for DMD, with expectations to have four clinical-stage programs by the end of 2026 [1][2] - The company has made significant progress in its EEV (endosomal escape vehicle) portfolio, particularly for neuromuscular diseases [3][4] - Upcoming data releases include: - ENTR-601-44 program: Top-line data expected in Q2 2026 - ENTR-601-45 program: First cohort data expected in mid-2026 - ENTR-601-50 program: Data expected by year-end 2026 [6][7][8] Financial Position - As of the end of 2025, Entrada had approximately $296 million in cash, providing a runway into Q3 2027 [10][43] Differentiation and Competitive Advantage - Entrada's approach utilizes a differentiated endosomal escape vehicle platform, achieving a 25-fold improvement in endosomal escape compared to competitors [11][18] - The company emphasizes low drug doses with high concentrations, reducing the risk of exposure and antibody response [12][29] - The strategy includes running clinical studies outside the U.S. to gather data for FDA discussions on accelerated approval [13][16] DMD and DM1 Programs - The DMD program aims for double-digit dystrophin production, which is crucial for efficacy [14] - The partnership with Vertex for the DM1 program includes significant financial incentives, with a total of $485 million in milestones [34] - The DM1 program is expected to complete enrollment and dosing by mid-2026 [35] Expansion into Ocular Diseases - Entrada announced its expansion into inherited retinal diseases, specifically targeting Usher syndrome type 2A, with a candidate named ENTR-801 [36][38] - This program addresses a significant unmet need, with approximately 15,000 patients in the U.S. and Europe lacking therapeutic options [37] Future Growth and Strategy - Entrada plans to continue expanding its pipeline into other intracellular targets and ocular diseases, with a focus on optimizing oligonucleotides and exploring new therapeutic areas [39][41] - The company aims to establish itself as a leader in the DMD space, with a substantial patient population of over 14,000 in the U.S. and Europe [33] Important but Overlooked Content - The company’s strategy includes a focus on safety, with no treatment-related adverse events reported in healthy volunteer studies [22] - The ability to achieve clinically relevant exon skipping and measurable protein production for at least 90 days in the ocular program is a significant milestone [38] - Entrada's approach to kidney safety is noteworthy, as it limits the risk of toxicity while increasing efficacy [29] This summary encapsulates the critical aspects of Entrada Therapeutics' conference call, highlighting its strategic direction, clinical advancements, and financial health.

Core Insights - Entrada Therapeutics is advancing its RNA-based therapeutic pipeline, focusing on neuromuscular and ocular diseases, with significant data expected in 2026 [2][3] Clinical Development Pipeline - The company is on track to report data from the first cohort of the ELEVATE-44-201 study in Q2 2026 and from ELEVATE-45-201 in mid-2026 [1][3] - Entrada plans to initiate a global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and submit regulatory applications for ENTR-601-51 in 2026 [1][3] - The company has completed dosing of Cohort 1 for ENTR-601-44 and is transitioning to the open-label Phase 2 portion [3] - ENTR-801 has been selected as the first clinical candidate for treating Usher syndrome type 2A, with a second candidate expected to be nominated in 2026 [1][5] Financial Position - Entrada has a cash runway anticipated into Q3 2027, indicating strong financial health to support ongoing and future clinical programs [1][6] Upcoming Events - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its development progress [2][7]